Tickertape - Financial freedom begins here

The Cabinet Committee on Economic Affairs has given its approval for the Minimum Support Price (MSP) for copra for 2026 season. In order to provide remunerative prices to the cultivators, Government had announced in the Union Budget of 2018-19, that MSP of all the mandated crops will be fixed at levels of at least 1.5 times of all India weighted average cost of production. The MSP for Fair Average Quality of milling copra has been fixed at Rs.12,027/- per quintal and for ball copra at Rs.12,500/- per quintal for 2026 season. The MSP for 2026 season is an increase of Rs.445/- per quintal for milling copra and Rs.400/- per quintal for ball copra over the previous season. The Government has increased MSP for milling copra and ball copra from Rs.5,250 per quintal and Rs.5,500 per quintal for the marketing season 2014 to Rs.12,027 per quintal and Rs.12,500 per quintal for the marketing season 2026, registering a growth of 129 percent and 127 percent, respectively. A higher MSP will not only ensure better remunerative returns to the coconut growers but also incentivize farmers to expand copra production to meet the growing demand for coconut products both domestically and internationally.Powered by Capital Market - Live

According to an exchange filing, the order is for the supply of a wireline winch, including a power pack and related equipment, and has been awarded in the ordinary course of business. The contract is scheduled to be executed within three months. The company further clarified that neither its promoters nor members of the promoter group have any interest in the awarding entity. Accordingly, the transaction does not qualify as a related-party transaction under applicable regulatory norms. United Drilling Tools is a leading manufacturer of oil drilling-related equipment in the country. The company has obtained global quality standards for its major products. The company's consolidated net profit surged 38.9% to Rs 5.75 crore on a 13.8% jump in revenue from operations to Rs 55.60 crore in Q2 FY26 over Q2 FY25. The counter shed 0.14% to settle at Rs 209.85 on the BSE.Powered by Capital Market - Live

This follows an earlier settlement that addressed the U.S. and Canadian markets. The agreement clears the way for Biocon Biologics to commercialize Yesafili globally. Yesafili is a vascular endothelial growth factor (VEGF) inhibitor used to treat multiple ophthalmology conditions, including neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), diabetic macular oedema (DME), and myopic choroidal neovascularisation (myopic CNV). As part of the agreement, all pending litigation among Biocon Biologics, Regeneron, and Bayer has been dismissed. Biocon Biologics plans to launch Yesafili in the United Kingdom in January 2026, followed by launches in other settled countries in March 2026, or earlier in certain circumstances. The other terms of the settlement remain confidential. The European Commission (EC) and the Medicines & Healthcare products Regulatory Agency (MHRA) have previously approved YESAFILI. Yesafili has already received approval from the European Commission (EC) and the UK Medicines & Healthcare products Regulatory Agency (MHRA). Biocon Biologics had earlier secured market entry for the U.S. in April 2025, targeting the second half of calendar year 2026, and launched the product in Canada earlier this year, with market entry secured in March 2024. Shreehas Tambe, CEO & managing director, Biocon Biologics, said, 'This settlement paves the way for Biocon Biologics to make available our biosimilar Aflibercept globally. This milestone expands our presence in the ophthalmology therapeutic area as we work closely with healthcare systems to increase access to patients everywhere.' Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases. On a consolidated basis, Biocon reported net profit of Rs 84.50 crore in Q2 September 2025 as against net loss of Rs 16 crore in Q2 September 2024. Net sales rose 20.24% YoY to Rs 4262.50 crore in Q2 September 2025. The counter added 1.34% to currently trade at Rs 386.65 on the BSE. Powered by Capital Market - Live

The Reserve Bank of India has sanctioned the Scheme of Amalgamation of The Amod Nagric Co-operative Bank Ltd., Amod, Gujarat with The Bhuj Mercantile Co-operative Bank Ltd., Ahmedabad, Gujarat. All the branches of The Amod Nagric Co-operative Bank Ltd., Amod, Gujarat will function as branches of The Bhuj Mercantile Co-operative Bank Ltd., Ahmedabad, Gujarat with effect from December 15, 2025. The Reserve Bank of India has sanctioned the Scheme of Amalgamation of Amarnath Co-operative Bank Ltd., Ahmedabad, Gujarat with The Kalupur Commercial Co-operative Bank Ltd., Ahmedabad, Gujarat. All the branches of Amarnath Co-operative Bank Ltd., Ahmedabad, Gujarat will function as branches of The Kalupur Commercial Co-operative Bank Ltd., Ahmedabad, Gujarat with effect from December 15, 2025. The Schemes will come into force with effect from December 15, 2025 (Monday). Powered by Capital Market - Live